The multifunctional E4F1 protein is a cellular target of the E1A adenoviral oncoprotein. Interaction between E4F1 and the hepatitis B virus (HBV) protein HBx has been demonstrated in vitro. In this study, RNA interference has been used to downregulate E4F1 in the hepatocellular carcinoma (HCC) cell line HepG2 (HBV negative) and its derivative, HBV expressing HepG2/2.2.15. Reduction of E4F1 levels induced hepatocyte vacuolation (formation of large cytoplasmic vesicles), increased autophagy and caused mitochondrial defects and metabolism changes in HepG2/2.2.15, but not in HepG2. Moreover, downregulation of E4F1 reduced DNA synthesis with partial cell cycle arrest in G 1 in both cell types and this effect was more marked in HepG2/2.2.15 than in HepG2. These effects were partially prevented by RNA interference directed to either HBx or to p53. Coprecipitation and western blot experiments detected complexes between E4F1 and HBx in several HCC cell lines. Although a review of mutation and gene expression public databases did not support that E4F1 is specifically altered in liver cancer, our results suggest that E4F1 may neutralize the capacity of HBx to activate a p53-dependent, metabolic and growth arrest phenotype in liver cells, thus possibly contributing to the viability and proliferation of HBV-infected cells.
Introduction
The transcription factor E4F1 is involved in proliferation control, oxidative metabolism and survival of embryonic and somatic adult stem cells. Initially identified as cellular target of E1A adenovirus protein and as transcriptional regulator of adenovirus E4 gene promoter (1-3), E4F1 also represses cyclin A promoter and downregulates cell cycle progression (4) . E4F1 exerts an unconventional ubiquitin-ligase activity, which stabilizes the tumor suppressor protein p53 and promotes its activation leading to growth suppression (5) . Mouse embryos lacking E4F1 die at an early developmental stage, whereas enforced expression of E4F1 in cell lines inhibits cell cycle progression (6) (7) (8) (9) . Moreover, conditional inactivation of E4F1 in mouse epidermis alters the maintenance and renewal of epidermal stem cells (ESC), as evidenced by transient epidermal hyperplasia followed by rapid cell loss, hyperkeratosis and severe skin ulcerations. This phenotype is consistent with rapid exhaustion of the ESC pool and is rescued by Bmi1 overexpression or by depletion of Ink4a/Arf or p53 (10, 11) . On the other hand, depletion of E4F1 in a mouse histiocytic sarcoma induced by transplanted Ink4a/Arf fetal liver cells, results in oxidative stress in tumor cells, with increased autophagy and apoptosis of tumor cells and tumor regression (12) .
In vitro studies (yeast double hybrid experiments) have shown that E4F1 interacts with a truncated hepatitis B virus (HBV) protein HBx (residues 18-142, lacking N-terminus). HBx independently interacts with two zinc finger domains of E4F1 (13) . HBx is a multifunctional and potentially oncogenic protein that is produced very early after infection and throughout the chronic infection phase (14) (15) (16) . It acts by interacting with cellular proteins and activating several signaling pathways, inducing the transcription of genes involved in regulation of cell growth, apoptosis, proliferation and DNA repair (14, (17) (18) (19) . Moreover, HBx has recently been shown to enhance autophagy in hepatoma cells infected with HBV (20) (21) (22) . Given the many potentially oncogenic roles of HBx, the interaction between E4F1 and HBx could be critical for proliferation, metabolic adaptation and survival of hepatocytes infected by HBV. However, this interaction and its biological roles in liver cells have never been demonstrated so far.
In this study, we have used the hepatocellular carcinoma (HCC) cell lines HepG2 and their derivative HepG2/2.2.15 (expressing a cloned HBV genome) to downregulate E4F1 in a context of expression of HBV or not. Silencing of E4F1 induced cytoplasmic vacuolation and metabolic changes and repressed cell cycle progression in HepG2/2.2.15, but not in HepG2. Furthermore, E4F1 and HBx interacted in cultured HCC cells. These effects were partially rescued by silencing HBx and/or p53, suggesting that E4F1 may play an important role upstream of an HBx-p53 pathway that controls the proliferation and metabolism of HCC cells.
Materials and methods

Cell lines and cultures
HepG2 (ATCC HB-8065), Hep3B (ATCC HB-8064) or PLC/PRF/5 (ATCC CRL-8024), Mahlavu were cultured at 37°C under 5% CO 2 , in minimum essential medium (Invitrogen™, Carlsbad, CA) supplemented with 10% fetal calf serum (Invitrogen™), 100 UI/ml penicillin, 100 μg/ml streptomycin, 2 mM glutamine (Sigma-Aldrich, St Louis, MO), non-essential amino acids and 1 mM sodium pyruvate (both from Invitrogen™). HepG2/2.2.15 cells were cultured at 37°C under 5% CO 2 , in Dulbecco's modified Eagle's medium high glucose (4.5 g/l) plus 10% fetal calf serum (Invitrogen™), 100 UI/ml penicillin, 100 μg/ml streptomycin, 2 mM glutamine (Sigma-Aldrich) and 2 mM sodium pyruvate (both from Invitrogen™) with a final concentration of 200 mg/l G418. containing HiPerfect (6 μl/well) (Qiagen) and 20 nM p53 small interfering RNA (siRNA) (5#-CAAUGGUUCACUGAAGACCTT-3# and 5#-GGUCUUCA GUGAACCAUUGTT-3#) or a control (scramble) siRNA (5#-CAUAGAU UACCGUGAGCACTT-3# and 5#-GUGCUCACGGUAAUCUAUGTT-3#) and/or 9.5 nM HBx siRNA (5#-ACAUAAGAGGACUCUUGGATT-3# and 5#-UCCAAGAGUCCUCUUAUGUTT-3#) (Eurogentec, Seraing, Belgium), or 20 nM E4F1 siRNA (5#-GGAUUUUGUUCAGCACAAGTT-3# and 5#-CUUGUGUCUGAACAAAAUCCTC-3#) (Applied Biosystems, Ambion, St Aubin, France). HBx siRNA was designed targeting the specific area of HBx in the genome of HBV (23) . Cells were recovered and analyzed 24 or 48 h after transfection.
RNA silencing and reverse transcription-quantitative polymerase chain reaction
The quantification of HBx, p53 and E4F1 gene expression was performed in three independent experiments by real-time PCR on a Stratagene® Mx3000P™ System according to the manufacturer's recommendation. Briefly, RNA was extracted from different cell lines using the RNA extraction kit (Qiagen) and reverse transcribed with the iScript Reverse Transcription supermix for reverse transcription-quantitative polymerase chain reaction Abbreviations: BrdU, bromodeoxyuridine; ESC, epidermal stem cell; GFP, green fluorescent protein; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; IP, immunoprecipitation; ld, lipid droplet; NMR, nuclear magnetic resonance; PBS, phosphate-buffered saline; siRNA, small interfering RNA.
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(Bio-RAD). The complementary DNA was then diluted five times for quantitative PCR. Quantitative PCR reactions were carried out in a total volume of 10 μl on 25-50 ng of complementary DNA using TaqMan Universal Master Mix (Applied Biosystems) and Universal Probe Library assays were designed with the Probe Finder software (Roche Applied Science). Reactions included an initial step of 2 min at 50°C and 10 min at 95°C, followed by 49 cycles of 15 s at 95°C and 40 min at 60°C. All reactions were run in triplicate, and the average values were used for quantification. Relative fold differences were determined by the ΔΔCt method with glyceraldehyde 3-phosphate dehydrogenase as endogenous control to normalize the expression.
Western blot and coimmunoprecipitation
The whole-cell protein extracts were obtained by lysing cells in radioimmunoprecipitation assay-like buffer (50 mM Tris-HCl, pH 7.4, 250 mM
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NaCl, 2 mM dithiothreitol, 0.1% sodium dodecyl sulfate, 0.5% NP40 and protease inhibitors). For subcellular fractionation, cytoplasmic and nuclear proteins were extracted from HepG2/2.2.15, HepG2, PLC/PRF/5 and Hep3B cells using NE-PER® Nuclear and Cytoplasmic Extraction Reagents (Thermo Fisher Scientific, Waltham, MA) according to the manufacturer's protocol. Equal amounts of proteins were resolved into 10 or 
12.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to polyvinylidene difluoride membranes (Roche Applied Science), probed with appropriate antibodies and revealed with enhanced chemiluminescence (Amersham, Buckinghamshire, UK). The following antibodies were used: mouse monoclonal anti-p53 (DO-7; Dako, Glostrup, Denmark, 1:3000), rabbit polyclonal anti-p53 (CM1; Novocastra, Wetzlar, Germany, 1:5000), rabbit polyclonal anti-Ku protein 80 kDa (Serotec, Oxford, UK; 1:40 000), rat monoclonal anti-HA-peroxidase (3F10; Roche Applied Science, 1:1000), mouse monoclonal anti-HBx (X36C; Alexis Biochemicals®, Farmingdale, NY, 1:1000), mouse monoclonal anti-β-tubulin (TUJ1; Covance®, Princeton, NJ, 1:1000), rabbit polyclonal anti-LC3 and p62/SQSTM1 (Sigma) and anti-E4F1 (BC2, Dr Le Cam, Montpellier, France).
For immunoprecipitation (IP) analysis, 1.10 6 cells were transfected with 500 ng of pWPT-GFP-HBx or pcDNA3-HA-HBx. As a measure of transfection efficiency, cells were harvested 48 h posttransfection and the percentage of green fluorescent protein (GFP)-positive cells (40% of the total cell population) was determined using fluorescence-activated cell sorting analysis. Cells were lysed in radioimmunoprecipitation assay lysis buffer or NE-PER® Nuclear Extraction Reagents containing protease inhibitors (Roche Molecular Biochemicals) for 40 min at 4°C and precleared using 1 μg of normal IgG for 1 h. IP was performed overnight at 4°C with polyclonal E4F1 antibody (BC2, donated by Dr Le Cam), or anti-HBx (DP2011; Acris Antibodies, Herford, Germany), or rat monoclonal anti-HA (3F10; Roche Applied Science) or rabbit polyclonal anti-GFP (FL; Santa Cruz Biotechnology), and 25 μl protein A-agarose in a total volume of 250 μl (Sigma-Aldrich, Lyon, France). Immunoprecipitates were then washed three times with radioimmunoprecipitation assay lysis buffer containing protease inhibitors or NE-PER® Nuclear Extraction buffer, resolved using sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and detected by immune blot analysis.
Confocal microscopy
Cells were grown on coverslips, washed in phosphate-buffered saline (PBS), fixed with 2% formaldehyde in PBS for 5 min at room temperature, permeabilized with 0.2% Triton X-100 in PBS for 5 min, washed with PBS, cells were stained with anti-α-tubulin, Alexa-fluor® 555 (Chemicon, Millipore) for 1 h, and then using DAPI Vectashield mounting medium (Vector laboratories, Burlingame, CA). The fluorescent samples were examined with a Zeiss laser scanning confocal microscope LSM 510 on Axiovert 200M. The LSM 4.0 sp1 (Zeiss, Jena, Germany) software was used for image acquisition and analysis.
Electronic microscopy
Cells were incubated in a mixture of 1 vol of 4% glutaraldehyde and 1 vol of cultured cell medium for 20 min at 4°C. They were further fixed in 2% gluteraldehyde in 0.2 M sodium cacodylate buffer, pH 7.4 for 30 min at 4°C, and postfixed with 1% osmium tetroxide with 0.8% K 4 FeCN 6 in cacodylic buffer for 1 h at room temperature. The material was dehydrated in an ethanol gradient (30, 50, 70, 80, 90, 96 and 100%) followed by propylene oxide and embedded in Epon 812. Blocks were cut with an LKB-Nova microtome and stained with 9% uranyl acetate and Reynolds solution. Samples were analyzed and photographed using a JEOL 1200 EX electron microscope at 80 kV.
Flow cytometry
Analysis of bromodeoxyuridine (BrdU) incorporation was performed using the BrdU Flow Kit (BD™ Biosciences) in accordance with the manufacturer's instructions. Cell cycle analysis was performed after ethanol fixation, ribonuclease digestion and propidium iodide staining. Cultured cells were stained with FITC-annexin V (Becton Dickinson, Canaan, CT) and propidium iodide (50 μg/ml) in accordance with the manufacturer's instructions, and analyzed by flow cytometry. Mitosis phase analysis used the Alexa Fluor® 647 Rat anti-histone H3 (pS28) antibody (BD™ Biosciences) according to the protocol provided. Analysis of mitochondrial membrane potential was carried out using the MitoProbe Dilc 1 (5) Assay Kit for Flow Cytometry (Molecular Probes, Invitrogen) according to the manufacturer's protocol.
Hematoxylin-eosin and red oil O staining
Cells were fixed in 10% formaldehyde for 30 min, and then were subjected to standard hematoxylin-eosin staining. To stain red oil O, cells were pretreated with 60% isopropanol for 30 s and stained with red oil O (Sigma-Aldrich®) in 60% isopropanol for 30 min. The cells were then washed with 60% isopropanol for 30 s, and then washed by cold water three times. Then cells were mounted with one drop of Crystal/Mount™ (Biomedia Corp, Foster City, CA; M02). Nikon digital camera dxm1200 (Nikon Champigny-sur-Marne, France) was used for observation. Images were captured and enhanced by using the software ACT-1 (version 2.12).
H-NMR high-resolution magic angle spinning spectroscopy analysis
Cells (4 × 10 5 ) were seeded in six-well plates, and transfected for 48 h with E4F1 or scramble siRNA as described above. Cells were then harvested by trypsinization and the cell pellet (32 × 10 6 ) was washed in a freshly prepared 0.9% NaCl solution in D 2 O (D215B-deuterium oxide 100%; CortecNet, Voisin-Le-Bretonneux, France). After gentle homogenization in 250 μl of NaCl/D 2 O solution, the cell suspension was distributed in 24 independent 30 μl disposable nuclear magnetic resonance (NMR) inserts (B4495; CortecNet) and immediately stored at −80°C until analyzed. Experiments were performed on a Bruker 700 MHz Advance II spectrometer, equipped with a 4 mm high-resolution magic angle spinning probe. The temperature was controlled at 295 K throughout the experiments. For each sample, a 1D NOESY 1 H-NMR spectrum with water presaturation was recorded to derive a metabolic profile. Spectra were manually phased and baseline corrected and divided into 10-30 p.p.m. wide buckets. The water area was excluded (δ = 4.5-5.18 p.p.m.). Data were normalized with the probabilistic quotient normalization procedure and mean centered. A multivariate analysis based on the orthogonal projection to latent structure algorithm was performed to evaluate discrimination between groups. Univariate metabolite analysis, using the non-parametric Wilcoxon rank sum test was used, on recoupled clusters of variables (Statistical Recoupling of Variables method) with a significance level of 0.05.
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Evaluation of E4F1 expression and mutation status in liver cancer
To evaluate whether variations in the expression of E4F1 may contribute to carcinogenesis, a qualitative screen of the public data on E4F1 expression in genome-wide expression studies on primary liver cancers and on liver cancer cell lines was performed. The Databases Oncomine (https:// www.oncomine.org/resource/main.html), Liverome (http://liverome.kobic. re.kr/index.php) and Gene Expression Omnibus (http://www.ncbi.nlm. nih.gov/geo/) were filtered using keywords 'liver', 'human' and 'E4F1' to identify studies pertaining to expression of E4F1 in human liver cancer samples compared with normal or adjacent non-involved liver tissue. Expression data was acquired from deposited gene expression datasets and, when appropriate, tumor/normal expression ratios were recalculated. The COSMIC database was searched to evaluate E4F1 mutations in liver cancers using keywords 'E4F1' and 'liver' (http://cancer.sanger.ac.uk/ cancergenome/projects/cosmic/).
Statistical analyses
The means of each treatment group were calculated for all experiments. The number of samples was indicated in the description of each experiment. Statistical analysis was carried out using the Student's t-test. A P value of <0.05 was considered significant. The NMR data was analyzed as described by Pontoizeau et al. (24) . H-NMR spectra of the 51 samples. Panel 2, corresponding metabolic signature discriminating siE4F1-transfected and scr-transfected cells, colored for correlation according to significance in multivariate analysis. Spectra were manually phased, baseline corrected, and calibrated on the alanine signal (CH3, δ =1.48 p.p.m.). The spectra were divided in 0.001 p.p.m. wide buckets over the 0.5-8.6 p.p.m. range. The water area was excluded (δ = 4.5-5.18 p.p.m.). Spectra were normalized with the probabilistic quotient normalization method and mean centered. A multivariate analysis based on the orthogonal projection to latent structure algorithm was performed to evaluate discrimination between groups.
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Results
Downregulation of E4F1-induced cytoplasmic vacuolation in HCC cells expressing HBV
The HCC-derived HepG2 line is HBV negative. HepG2/2.2.15 is derived from the former by expression of a complementary DNA encoding HBV genotype D and assembles viral particles in vitro (25) . We have used siRNA to decrease E4F1 expression in these cells by on average 75%, and we have analyzed the effects of this downregulation on cell phenotype (Figure 1 ). Significant differences were observed in the patterns of intracytoplasmic vesicles between the two cell lines. Although in HepG2, downregulation of E4F1 had no significant effect on vesicle numbers and overall cell morphology, Increased formation of vesicles was detected by light microscopy in HepG2/2.2.15 cells ( Figure 1A) . Moreover, many HepG2/2.2.15 cells exhibited large vesicles that filled in the cytoplasm, pushing the nucleus against the plasma membrane, a process described as cytoplasmic vacuolation ( Figure 1B) . By electron microscopy, the majority of the vesicles in HepG2 were <2 μm diameter and downregulation of E4F1 did not significantly change the number, distribution and overall shapes of these vesicles ( Figure 1C, upper panel) . These vesicles were in majority small lipid droplets (ld; homogeneous, amorphous regular droplets with no apparent outer membrane structure) (Supplementary Figure  S1 , available at Carcinogenesis Online). In contrast, in HepG2/2.2.15, a diversity of vesicles with different types and shapes was detected, including double-membraned autophagosomes (av), ld, mixed structures presenting the features of ld with partial double membrane structures that were similar to autophagy vesicles (ld+av), and single membrane multivesicular bodies (one-mb) ( Figure 1D , column 1). These types of vesicles were also detected in cells treated with siRNA to E4F1 ( Figure 1D, column 2) . In addition, much larger vesicles (up to 8 μm) were also observed, which were infrequent or absent in untreated cells ( Figure 1D, columns 3 and 4) . The largest vesicles (column 4) presented features suggestive of atypical autophagy, partially double membrane vesicles ( Figure 1D, 4a) , multishaped vesicles with partially double membrane structures and ld ( Figure 1D , 4b) and single membrane, apparently empty vesicles ( Figure 1D , 4c). Semiquantitative evaluation of the average number of vesicles in the two cell types was performed by counting representative electron microscopy microphotographs ( Figure 1E ). In HepG2, downregulation of E4F1 did not induce significant changes in number and types of vesicles. In HepG2/2.2.15, however, there were significant increases in numbers of small (<2 μM) and large (≥2 μM) vesicles and in autophagy vesicles. In contrast, the numbers of ld were not significantly increased. This observation was confirmed by using red oil O to stain lipids ( Figure 1F ). In HepG2/2.2.15 with siRNA to E4F1, the majority of the large vesicles were not stained by red oil O. Figure 1G shows that transfection of siRNA reduced E4F1 messenger RNA by ~75% in both cell lines, with a compatible decrease in p120 E4F1 protein levels. Although those decreases correspond to attenuated expression rather than complete silencing, our results show a profound modification of the patterns of intracytoplasmic vesicles in HepG2/2.2.15, but not in HepG2 cells.
Effects of downregulation of E4F1 on autophagy, metabolism and proliferation
The differences in the patterns of intracytoplasmic vesicles between the two cell lines and the changes observed in HepG2/2.2.15 after silencing E4F1 were suggestive of altered autophagy and of cell metabolism. To determine whether the changes observed in intracellular vesicle patterns in HepG2/2.2.15 cells may correspond to increased autophagy, we first assessed the conversion of LC3-I protein into membrane-bound LC3-II and the reduction of expression of p62/SQSTM1 (p62), two biochemical hallmarks of autophagy (26) . Increased LC3-II is a marker for the formation of double membrane autophagosomes (an early step in autophagy), whereas decreased level of LC3-II occurs during autophagosomes fusing with lysosomes to form autolysosomes (27) . Decreased p62 is a marker of protein digestion in autolysosomes (a later step in autophagy) (28, 29) . Figure 2A shows that the levels of both p62 and LC3-II were decreased by ~25 and 50%, respectively, in HepG2/2.2.15 treated with siRNA to E4F1. These results are consistent with our observation of accumulation of large vesicles with features of autolysosomes (20) , suggesting that HepG2/2.2.15 cells have an atypical autophagic process, in which the recycling of autolysosomes step is impaired.
Next, we used a fluorescent marker, DilC 1 (5), to assess mitochondrial membrane potential disruption in HepG2/2.2.15. A reduction in DilC 1 (5) fluorescence was detected after silencing E4F1, indicating profound mitochondrial defects ( Figure 2B ). Effects on cell metabolism were detected by 1 H-NMR using the high-resolution magic angle spinning technique, which allows analyzing patterns of metabolites in intact cells ( Figure 2C ). Orthogonal projection to latent structure analysis distinguished HepG2/2.2.15 with silenced E4F1 (siE4F1) from cells treated with control siRNA (scr) ( Figure 2C, panel 1) . In HepG2/2.2.15, differences in specific metabolites were detected, between cells with or without siRNA to E4F1. These differences included reduction in glutamate, glutathione, acetate and leucine as well as increases in phosphocholine, in lipid glycerol and in several lipid species (Figure 2C, panel 2 and Supplementary Table S1 , available at Carcinogenesis Online). Several of these changes point to an increase in intracellular oxidative stress (30) (31) (32) , compatible with altered mitochondria defects, whereas changes in lipid precursors and in several lipid species are indicative of altered lipid metabolism.
To monitor the effect of E4F1 on cell proliferation and survival, we analyzed cell cycle distribution by flow cytometry (Figure 3) . A tendency toward reduction in BrdU incorporation (48-36%) and increase in G 1 phase (51.6-63.1%) was observed in HepG2 ( Figure 3A , left and Figure 3B ). In contrast, HepG2/2.2.15 cells showed an increase in G 1 phase (from 59.7 to 76.1%) and over 50% decrease in both S and in G 2 /M phases ( Figure 3C ). The decrease in S phase was accompanied by a reduction of 45% in BrdU incorporation ( Figure 3A, right) . No significant increase in apoptosis was detected using Annexin V as a marker in HepG2/2.2.15 (Supplementary Table S2 , available at Carcinogenesis Online).
Overall, these results indicate that silencing of E4F1 in HepG2/2.2.15 cells induced changes in cell metabolism, with atypical autophagy, impaired mitochondrial function, decreased glutathione/ glutamate metabolism and increased biosynthesis of lipids, perhaps as a result of increased formation of lipid membranes during the accumulation of large intracellular vesicles. Despite altered mitochondrial membrane potential and increased oxidative stress, HepG2/2.2.15 with decreased E4F1 expression underwent cell cycle arrest rather than apoptosis.
Downregulation of HBx partially rescued the phenotype induced by E4F1 silencing in HepG2/2.2.15
The results above suggest that while decreasing the expression of E4F1 has only minor effect on HepG2, it has an important effect on the morphology, metabolism and proliferation in HepG2/2.2.15, a derivative cell line expressing HBV. There is a strong evidence suggest that HBV regulates autophagy through several of its protein components, in particular HBx (20, 21) . Since HBx is considered as the main HBV modulator of liver cell signaling and proliferation (14), we used siRNA silencing to determine whether downregulation of HBx could revert the effects induced by inhibition of E4F1 (Figure 4) . Figure 4A shows that double silencing of E4F1 and HBx attenuated the formation of large vesicles detected when silencing E4F1 alone. This effect was not due to restoration of initial levels of E4F1 ( Figure 4B ). Using BrdU incorporation to measure DNA synthesis, silencing HBx decreased BrdU incorporation by 40%, compared with 58% when silencing E4F1. In double-silenced cells, the decrease was of 40%, similar to silencing HBx ( Figure 4C ). Cell cycle analysis showed similar distribution between phases in cells with siRNA to HBx or with both siRNA to HBx and to E4F1 ( Figure 4D ). Since E4F1 is required for mitotic progression in mouse embryonic fibroblasts (8), we used phospho-HH3 as a marker of mitosis. Although a decrease of 20% was observed after E4F1 silencing in HepG2, a stronger decrease (43%) was detected in HepG2/2.2.15 ( Figure 4E ). After silencing of either HBx or both HBx and E4F1, this decrease was of 23 and 28%, respectively ( Figure 4F ). Overall, these results indicate that, while silencing HBx has an effect on the proliferation of HepG2/2.2.15 cells, it attenuates the effects of E4F1 silencing on intracytoplasmic vesicle formation and on cell proliferation.
Complex formation between E4F1 and HBx
Complex formation between E4F1 and HBx has been demonstrated using yeast double hybrid assays. To identify such complexes in intact cells, we have performed IP in HCC cell lines ( Figure 5 ). First, we used cytoplasmic and nuclear cell extracts in western blot to analyze the distribution of the two proteins. In addition to HepG2 and
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HepG2/2.2.15, we used two other cell lines containing HBx, PLC/ PRF/5 and Hep3B. The predominant nuclear localization of E4F1 was confirmed in HepG2 and in PLC/PRF/5 ( Figure 5A ). With respect to HBx, the protein expressed in HepG2/2.2.15 or in PLC/PRF/5 was mostly detected in the cytoplasm. The detection signal was very low, consistent with the notion that HBx is expressed at low levels in these cells ( Figure 5B, lower panel) . To detect complexes between E4F1 and HBx, we used an HA-HBx construct transfected in HepG2. In these conditions, HBx was detected in the cytoplasm and nucleus ( Figure 5B, upper panel) . Comparison of IP of whole-cell extracts with antibodies to E4F1, HBx (positive control) or actin (negative control) identified HA-HBx in complex with E4F1 at levels similar to those detected with positive control antibody. A concordant result was observed in Hep3B transfected a GFP-HBx construct. In this system, IP was performed with either anti-E4F1 or anti-HBx antibodies and was followed by western blot either with anti-E4F1 (after IP with anti-HBx) or with anti-GFP (after IP with anti-E4F1). Complexes between E4F1 and HBx were detected in both cases ( Figure 5C ). These experiments show that the two proteins assemble into a complex when expressed in intact cells, although we could not demonstrate complexes in HepG2/2.2.15, perhaps due to low levels of HBx in these cells.
Since E4F1 may bind to the enhancer II region of HBV virus (13), we used an enzyme-linked immunosorbent assay to measure HBV surface antigen as a marker of HBV replication in HepG2/2.2.15 transfected with siRNA to E4F1, to HBx or with both. Inhibition of E4F1 increased HBV surface antigen expression ( Figure 5D ). In contrast, HBV surface antigen expression was repressed by siRNA to HBx sequences or to both HBx and E4F1. These results suggest that E4F1 represses HBV expression, a notion supported by the fact that siRNA to E4F1 increased HBx messenger RNA levels ( Figure 5E ). Thus, although E4F1 and HBx have the potential to form complexes, E4F1 may also repress HBV replication and HBx expression.
p53 as mediator of E4F1/HBx effects
The results above suggest that in HepG2/2.2.15, E4F1 interacts with HBx to control a suppressive activity of this viral protein. HepG2/2.2.15 harbors wild-type p53. To determine whether p53 plays a role in the suppressive effects induced by downregulation of E4F1, we analyzed the effects of E4F1 silencing in three liver cancer cell lines that lack functional p53, PLC/PRF/5 and Mahlavu (both expressing mutant p.R249S p53) and Hep3B (carrying a large deletion in the TP53 locus). Among these cells, Hep3B and PLC/PRF/5 express HBx, whereas Mahlavu does not (33) . Silencing of E4F1 had no effect on the formation of vesicles in any of these cell lines, and had a small effect on BrdU incorporation only in PLC/PRF/5, but not in the two other lines (Figure 6A-C) . We next used siRNA to silence p53 in HepG2 and HepG2/2.2.15. Silencing of p53 did not significantly increase BrdU incorporation in HepG2, although it neutralized the small decrease induced by silencing E4F1 ( Figure 6D ). In HepG2/2.2.15, however, silencing of p53 had a major effect ( Figure 6E and F) . Not only it increased BrdU incorporation by 40% (from 33 to 46%), but it also reversed the suppression of BrdU incorporation induced by silencing E4F1 (from 19 to 45%). Silencing of p53 also neutralized the accumulation of large vesicles after downregulation of E4F1 ( Figure 6G ). These experiments provide evidence that p53 is involved as a downstream effector in a growth suppression cascade induced by silencing E4F1 in HCC and hepatoma cells expressing HBV/HBx.
Expression of E4F1 in human liver tumors
To evaluate whether alteration of E4F1 expression may occur during hepatocarcinogenesis, we mined whole genome expression data from three public databases, Oncomine, Liverome and Gene Expression Omnibus, for data comparing of E4F1 expression levels between individual HCC samples and either matched samples of histopathologically normal liver tissues from the same patients or samples of normal tissues from control subjects without HCC.
Five published studies were identified, which collectively included a pool of 323 HCC cases and 225 controls (34) (35) (36) (37) (38) . Overall, these studies provide limited evidence in suggesting a small increase in E4F1 expression in liver cancer. Although the amplitude of the effect was extremely small (1.1-1.5-fold, depending upon studies), four of the five studies reported that this change was statistically significant (Table I ). In one study (38) , E4F1 was ranked 19th among a total of 465 genes upregulated at a threshold of P < 0.01. The same small effect was observed independently of HBV or hepatitis C virus infection status. Furthermore, a survey of 10 datasets comparing gene expression patterns between HBV and hepatitis C virus-related HCC did not identify E4F1 among a list of 382 differentially expressed genes (Supplementary Table S3 , available at Carcinogenesis Online).
E4F1 is located on chromosome 16p13.3, in a region that is not significantly affected by copy number variations or rearrangements in liver cancers. The COSMIC database contains E4F1 exome sequence information for 312 samples of liver cancer. No mutation has been identified, suggesting that this gene is extremely rarely targeted by mutations in HCC.
Discussion
E4F1 has important effects on ESC maintenance and on survival of myeloid leukemic cells but its roles in carcinogenesis are poorly understood (10, 12) . In vitro studies have identified that E4F1 forms complexes with the hepatitis B oncoprotein HBx (13) , but the role of this interaction in hepatocytes and in liver cancer cells has not been studied so far. Here, we show that E4F1 interacts with HBx in HCC cells, with effects on cell proliferation, metabolism and on the formation of intracellular vesicles associated with autophagy in cells that express HBV, but not in HBV-negative cells. Silencing of E4F1 expression profoundly modified the patterns of intracellular vesicles formation in HepG2/2.2.15 cells expressing HBV but not in parental, HBV-negative HepG2 cells. Upon E4F1 downregulation, HBVexpressing cells showed increased tendency to accumulate large intracytoplasmic vesicles with complex features, containing ld and fragments of atypical autophagy vesicles. These cells also showed reduction in proliferation, impaired mitochondrial status and changes in metabolites, including decreased glutamate and glutathione, 
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suggesting oxidative stress. This phenotype was prevented by simultaneous inhibition of E4F1 and HBx. Moreover, inhibition of p53 in HepG2/2.2.15 rescued the effects induced by inhibition of E4F1. Whether this effect is due to direct interactions between p53 and E4F1 and/or HBx, or to indirect mechanisms linking these factors with pathways regulating p53 activity (39) (40) (41) (42) , remains to be investigated.
Overall, these results identify E4F1 as a target for HBx protein binding in hepatocytes and suggest that E4F1 binding neutralizes some effects of HBV on cell metabolism, autophagy vesicle formation and processing, and proliferation. Furthermore, theses effects appear to be mediated, at least in part, by p53. We suggest that binding of E4F1 to HBx contributes to the long-term maintenance of HBV chronically infected cells.
In this study, we have used HepG2/2.2.15 cells that express the entire HBV genome, making it difficult to rule out interference by viral proteins other than HBx. Indeed, despite using siRNA sequences optimized for targeting invariant regions of HBx (23), the overlapping of HBV reading frames makes it possible that the expression of other HBV antigens may be affected. Another potential limitation is that HepG2 and HepG2/2.2.15, despite derived from the same cell source, may have genetically diverged since their establishment, causing for different biological responses.
E4F1 was initially identified as a target of adenoviral E1A oncogene and a transcriptional factor for adenovirus E4 promoter (1-3). Ablation of E4F1 by homologous recombination in mice causes mitotic defects in blastocysts such as lagging chromosomes, mitotic failure and cell death due to activation of the mitotic checkpoint (8) . Studies in ESC have shown that targeted deletion of E4F1 decreases clonogenic capacity in vitro and accelerates the exhaustion of pools of ESC in mouse skin in vivo. This skin phenotype is rescued by ablation of INK4A/p14ARF and/or TP53, as well as by overexpression of Bmi1 (10, 11) . These activities suggest that E4F1 plays a role in the maintenance of stem cell capabilities. E4F1 might be essential for correct mitosis in stem and progenitor cells and may become attenuated in differentiated cells.
In mouse myeloid cancer cells deleted for INK4a/p14ARF, ablation of E4F1 induces mitochondrial defects, release of reactive oxygen species and increased cell death by autophagy and/or apoptosis (12) . These effects are not observed in normal macrophages. It has been proposed that transformed myeloid cells have yet unidentified mitochondrial defects that sensitize them to the depletion of E4F1. Such cancer cells may be addicted to Y.Dai et al. 
